<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178761</url>
  </required_header>
  <id_info>
    <org_study_id>201402003RINA</org_study_id>
    <nct_id>NCT02178761</nct_id>
  </id_info>
  <brief_title>Imaging and Interventional Study for Erectile Dysfunction and Lower Urinary Tract Symptoms</brief_title>
  <acronym>PERFECT</acronym>
  <official_title>Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms: A Multi-modality, Multi-Specialty Collaborative Study (PERFECT Program)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erectile dysfunction is highly prevalent as men grow older. Among the various causes of
      erectile dysfunction, it has been shown that pelvic arterial insufficiency plays a very
      important role. The investigators have recently developed the first imaging analytical
      algorithm by using the abdominal/pelvis multidetector computed tomographic (MDCT) angiography
      to delineate the whole arterial system supplying the penis. To establish a comprehensive,
      cutting-edge diagnostic and interventional therapeutic program for erectile dysfunction, the
      investigators therefore design this series of studies by including experts from Urology,
      Radiology, and Cardiology. This research project (PERFECT program) includes the following 4
      sub-studies: 1) differential frequency of obstructive pelvic arterial lesions in coronary
      artery disease patients with and without erectile dysfunction/lower urinary tract symptoms
      (LUTS), 2) differential frequency of obstructive pelvic arterial lesions in patients with
      vascular risk factors and with or without erectile dysfunction/LUTS, 3) safety, feasibility,
      and efficacy of comprehensive pelvic angioplasty (with various interventional
      strategies/instruments) for patients with erectile dysfunction/LUTS and pelvic obstructive
      arterial disease: proof-of-concept study; and 4) efficacy and safety of comprehensive pelvic
      angioplasty (with various interventional strategies/instruments) for patients with erectile
      dysfunction/LUTS and pelvic obstructive arterial disease: a randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IIEF</measure>
    <time_frame>1 year</time_frame>
    <description>IIEF: Internal index for erectile function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EPS</measure>
    <time_frame>1 year</time_frame>
    <description>EPS: erectile hardness score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPSS</measure>
    <time_frame>1 year</time_frame>
    <description>IPSS: international prostate symptom score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CT angiographic binary restenosis</measure>
    <time_frame>1 year</time_frame>
    <description>CT angiographic binary restenosis: ≥50% lumen diameter stenosis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Any major adverse events</measure>
    <time_frame>1year</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Angioplasty alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>plain old balloon angioplasty alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stenting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Balloon angioplasty plus stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug-eluting balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Balloon angioplasty with drug-eluting balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>biodegradable vascular scaffold stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stenting with biodegradable vascular scaffold stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug-eluting balloon</intervention_name>
    <description>angioplasty completed with drug-eluting balloons</description>
    <arm_group_label>drug-eluting balloon</arm_group_label>
    <other_name>SeQuent® Please</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>biodegradable vascular scaffold stent</intervention_name>
    <description>Stenting with biodegradable vascular scaffold stents</description>
    <arm_group_label>biodegradable vascular scaffold stent</arm_group_label>
    <other_name>Absorb Bioresorbable Vascular Scaffold System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Apex™ PTCA Dilatation Catheter</intervention_name>
    <description>plain old balloon angioplasty alone</description>
    <arm_group_label>Angioplasty alone</arm_group_label>
    <other_name>TREK &amp; MINI TREK Coronary Dilatation Catheter</other_name>
    <other_name>Sprinter Legend RX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent System</intervention_name>
    <description>stenting with either bare-metal stents or drug-eluting stents</description>
    <arm_group_label>Stenting</arm_group_label>
    <other_name>Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System</other_name>
    <other_name>XIENCE PRIME Everolimus Eluting Coronary Stent System</other_name>
    <other_name>Resolute Integrity Coronary Stent System</other_name>
    <other_name>BioMatrix Flex™</other_name>
    <other_name>Nobori® Drug Eluting Stent</other_name>
    <other_name>MULTI-LINK 8 Coronary Stent System</other_name>
    <other_name>Integrity Coronary Stent System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men 20 years of age or older with &quot;consistent&quot; erectile dysfunction defined as both
             IIEF-5 scores, taken at least 4 weeks apart, are in the range of 5 to 21 points and
             with a difference of &lt;=2 points

          -  the anatomical inclusion criteria, based on pelvic CT angiography, are unilateral
             luminal diameter stenosis &gt;=70% or bilateral diameter stenoses &gt;=50% in the pelvic
             arteries with reference vessel diameter &gt;=2.5 mm and &lt;=4.0 mm and a target-lesion
             length &lt;=40 mm

        Exclusion Criteria:

          -  the arterial inflow to the penis is entirely from the accessory pudendal arteries
             rather than the usual internal pudendal artery and common penile artery;

          -  the presence of focal diameter stenosis &gt;=70% in the common iliac artery, internal
             iliac artery, or anterior division of internal iliac artery;

          -  previous radical prostatectomy, pelvic radiation, or Peyronie's disease;

          -  untreated hypogonadism (serum total testosterone &lt;300 ng/dL within 14 days before
             enrollment);

          -  acute coronary syndrome, stroke, or life-threatening arrhythmia within 3 months before
             enrollment;

          -  poorly controlled diabetes mellitus with glycosylated hemoglobin levels &gt;9%;

          -  serum creatinine levels &gt;2.5 mg/dL;

          -  bleeding diathesis or known hypercoagulopathy;

          -  life expectancy of fewer than 12 months;

          -  known intolerance to contrast agents
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tzung-Dau Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NTUH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tzung-Dau Wang, MD, PhD</last_name>
    <phone>+886-972651070</phone>
    <email>tdwang@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tzung-Dau Wang, MD, PhD</last_name>
      <phone>+886-972651070</phone>
      <email>tdwang@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Tzung-Dau Wang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Jeng Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Wang TD, Lee WJ, Yang SC, Lin PC, Tai HC, Hsieh JT, Liu SP, Huang CH, Chen WJ, Chen MF. Safety and six-month durability of angioplasty for isolated penile artery stenoses in patients with erectile dysfunction: a first-in-man study. EuroIntervention. 2014 May;10(1):147-56. doi: 10.4244/EIJV10I1A23.</citation>
    <PMID>24832642</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>June 30, 2014</last_update_submitted>
  <last_update_submitted_qc>June 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Multidetector Computed Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

